The main focus going forward is to take ONCOS-102 eagerly forward in
clinical development in PD1-refractory melanoma. The feedback and discussions
with the FDA have provided further guidance on what is the best next step, which
will be a platform trial in PD1 refractory melanoma. The trial is intended to
test ONCOS-102 in monotherapy and multiple combinations, including PD1
checkpoint inhibitor and potentially other novel immunotherapies to further
enhance the efficacy beyond the promising response rate we saw in our previous
melanoma trial. This will provide an opportunity to differentiate ONCOS-102 from
other approaches and potentially open up development avenues into the
commercially highly attractive front-line melanoma therapy indication.”



HVOR MANGE indikasjoner hvor Keytruda og Oncos kan ta store markedsandeler.... 1 - 5 - 10 - mer ?